Today, the President & CEO of VolitionRX (VNRX), Cameron John Reynolds, bought shares of VNRX for $4,664.
Following Cameron John Reynolds’ last VNRX Buy transaction on August 17, 2018, the stock climbed by 2.4%.
See today’s analyst top recommended stocks >>
Based on VolitionRX’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $17.1K and GAAP net loss of $4.18 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $4.48 million. The company has a one-year high of $6.84 and a one-year low of $1.67. Currently, VolitionRX has an average volume of 136.06K.
Starting in March 2019, VNRX received 11 Buy ratings in a row.
Cameron John Reynolds’ trades have generated a 27.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VolitionRX Ltd. is a multi-national life sciences company. It engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Singapore.
